Logo image of VXRT

VAXART INC (VXRT) Stock Fundamental Analysis

NASDAQ:VXRT - Nasdaq - US92243A2006 - Common Stock - Currency: USD

0.3439  -0.01 (-1.43%)

After market: 0.356 +0.01 (+3.52%)

Fundamental Rating

2

Taking everything into account, VXRT scores 2 out of 10 in our fundamental rating. VXRT was compared to 568 industry peers in the Biotechnology industry. Both the profitability and financial health of VXRT have multiple concerns. VXRT is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VXRT had negative earnings in the past year.
VXRT had a negative operating cash flow in the past year.
VXRT had negative earnings in each of the past 5 years.
VXRT had a negative operating cash flow in each of the past 5 years.
VXRT Yearly Net Income VS EBIT VS OCF VS FCFVXRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

VXRT's Return On Assets of -40.24% is in line compared to the rest of the industry. VXRT outperforms 56.34% of its industry peers.
With a Return On Equity value of -113.62%, VXRT perfoms like the industry average, outperforming 42.43% of the companies in the same industry.
Industry RankSector Rank
ROA -40.24%
ROE -113.62%
ROIC N/A
ROA(3y)-66.71%
ROA(5y)-50.62%
ROE(3y)-117.91%
ROE(5y)-83.49%
ROIC(3y)N/A
ROIC(5y)N/A
VXRT Yearly ROA, ROE, ROICVXRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

VXRT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VXRT Yearly Profit, Operating, Gross MarginsVXRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

1

2. Health

2.1 Basic Checks

VXRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VXRT has been increased compared to 1 year ago.
VXRT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for VXRT has been reduced compared to a year ago.
VXRT Yearly Shares OutstandingVXRT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
VXRT Yearly Total Debt VS Total AssetsVXRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

VXRT has an Altman-Z score of -4.88. This is a bad value and indicates that VXRT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.88, VXRT perfoms like the industry average, outperforming 40.85% of the companies in the same industry.
A Debt/Equity ratio of 0.03 indicates that VXRT is not too dependend on debt financing.
VXRT has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: VXRT outperforms 40.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -4.88
ROIC/WACCN/A
WACC10.21%
VXRT Yearly LT Debt VS Equity VS FCFVXRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

VXRT has a Current Ratio of 0.75. This is a bad value and indicates that VXRT is not financially healthy enough and could expect problems in meeting its short term obligations.
VXRT has a worse Current ratio (0.75) than 90.85% of its industry peers.
VXRT has a Quick Ratio of 0.75. This is a bad value and indicates that VXRT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.75, VXRT is not doing good in the industry: 90.67% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.75
VXRT Yearly Current Assets VS Current LiabilitesVXRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

8

3. Growth

3.1 Past

VXRT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.38%, which is quite impressive.
The Revenue has grown by 288.63% in the past year. This is a very strong growth!
The Revenue has been growing by 23.72% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
Revenue 1Y (TTM)288.63%
Revenue growth 3Y217.11%
Revenue growth 5Y23.72%
Sales Q2Q%367.95%

3.2 Future

The Earnings Per Share is expected to grow by 20.49% on average over the next years. This is a very strong growth
VXRT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 60.56% yearly.
EPS Next Y0.5%
EPS Next 2Y-6.21%
EPS Next 3Y17.4%
EPS Next 5Y20.49%
Revenue Next Year-69.18%
Revenue Next 2Y-51.77%
Revenue Next 3Y88.45%
Revenue Next 5Y60.56%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VXRT Yearly Revenue VS EstimatesVXRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M 200M 250M
VXRT Yearly EPS VS EstimatesVXRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VXRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VXRT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VXRT Price Earnings VS Forward Price EarningsVXRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VXRT Per share dataVXRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 -0.3

4.3 Compensation for Growth

A more expensive valuation may be justified as VXRT's earnings are expected to grow with 17.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.21%
EPS Next 3Y17.4%

More info and screens

0

5. Dividend

5.1 Amount

VXRT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VAXART INC

NASDAQ:VXRT (4/17/2025, 8:00:02 PM)

After market: 0.356 +0.01 (+3.52%)

0.3439

-0.01 (-1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-20 2025-03-20/amc
Earnings (Next)05-12 2025-05-12
Inst Owners15.79%
Inst Owner Change0%
Ins Owners0.85%
Ins Owner Change48.63%
Market Cap78.39M
Analysts86.67
Price Target4.76 (1284.12%)
Short Float %5.9%
Short Ratio6.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.08%
Min EPS beat(2)41.18%
Max EPS beat(2)50.98%
EPS beat(4)3
Avg EPS beat(4)-34.18%
Min EPS beat(4)-230.84%
Max EPS beat(4)50.98%
EPS beat(8)7
Avg EPS beat(8)-8.23%
EPS beat(12)9
Avg EPS beat(12)-5.37%
EPS beat(16)12
Avg EPS beat(16)-5.17%
Revenue beat(2)1
Avg Revenue beat(2)220.33%
Min Revenue beat(2)-28.31%
Max Revenue beat(2)468.97%
Revenue beat(4)3
Avg Revenue beat(4)1695.86%
Min Revenue beat(4)-28.31%
Max Revenue beat(4)6175.49%
Revenue beat(8)6
Avg Revenue beat(8)1297.27%
Revenue beat(12)6
Avg Revenue beat(12)837.64%
Revenue beat(16)6
Avg Revenue beat(16)616.69%
PT rev (1m)-3.45%
PT rev (3m)-3.45%
EPS NQ rev (1m)19.94%
EPS NQ rev (3m)37.31%
EPS NY rev (1m)12.95%
EPS NY rev (3m)12.95%
Revenue NQ rev (1m)-22.98%
Revenue NQ rev (3m)-22.89%
Revenue NY rev (1m)-55.07%
Revenue NY rev (3m)-55.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.73
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0.13
BVpS0.26
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.24%
ROE -113.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.71%
ROA(5y)-50.62%
ROE(3y)-117.91%
ROE(5y)-83.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.26%
Cap/Sales 1.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.75
Quick Ratio 0.75
Altman-Z -4.88
F-Score5
WACC10.21%
ROIC/WACCN/A
Cap/Depr(3y)64.4%
Cap/Depr(5y)72.15%
Cap/Sales(3y)3209.1%
Cap/Sales(5y)2046.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
EPS Next Y0.5%
EPS Next 2Y-6.21%
EPS Next 3Y17.4%
EPS Next 5Y20.49%
Revenue 1Y (TTM)288.63%
Revenue growth 3Y217.11%
Revenue growth 5Y23.72%
Sales Q2Q%367.95%
Revenue Next Year-69.18%
Revenue Next 2Y-51.77%
Revenue Next 3Y88.45%
Revenue Next 5Y60.56%
EBIT growth 1Y20.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.46%
OCF growth 3YN/A
OCF growth 5YN/A